Last updated: February 13, 2026
Overview:
NDC 00168-0424 corresponds to a specific drug marketed by Novartis, identified as "Gilenya" (fingolimod), used primarily for relapsing forms of multiple sclerosis (MS). The drug’s market dynamics are driven by its therapeutic efficacy, patent status, competition landscape, and regulatory framework, influencing its pricing and sales forecasts.
Market Size and Demand Drivers:
The global multiple sclerosis (MS) drug market was valued at approximately $21 billion in 2022. Gilenya held a significant share, estimated at 15-20% of the MS market, translating to sales around $3-4 billion annually [1]. Factors impacting demand include:
- Rising prevalence of MS worldwide, projected at 2.8 million cases globally, increasing at about 4.4% annually [2].
- Expanding treatment guidelines favoring oral disease-modifying therapies (DMTs), including fingolimod.
- Patient preference shifting from injectable to oral treatments.
Competitive Landscape:
Gilenya faces competition from other oral DMTs such as:
- Aubagio (teriflunomide)
- Tecfidera (dimethyl fumarate)
- Mavenclad (cladribine)
Injectables like Avonex and Tysabri also remain relevant, especially in specific patient segments. The competition influences market share and pricing.
Regulatory and Patent Timeline:
Gilenya received FDA approval in 2010 and EU approval in 2011, with key patents expiring in 2027-2028 [3]. Patent expiration typically leads to Biosimilar or generic entries, affecting price erosion.
Pricing Trends and Projections:
-
Current Pricing:
In the U.S., list prices for Gilenya are approximately $7, jetzt die https://www.goodrx.com/gn/single-drug-price/gilenya?drug_name=gilenya (as of 2023). Actual net prices, after discounts and rebates, are estimated around $4,000-$5,000 per month per patient.
-
Historical Price Trends:
Pricing has stabilized over the past five years, with minimal increases outside inflation adjustments. Patent expiration driven generic entry is projected around 2027-2028.
-
Future Price Projections:
Assuming patent expiration occurs in 2027, the market could witness:
- Initial price erosion of 20-40% within the first year of generic entry.
- Long-term price decline of 50-70% over five years post-generic introduction.
If generic fingolimod enters in 2027, annualized prices could fall to approximately $2,000-$3,000, with per-pill costs dropping proportionally.
| Sales Forecasts (2023–2030): |
Year |
Estimated Global Sales |
Notes |
| 2023 |
$3.2 billion |
Stabilized market, high brand loyalty |
| 2024 |
$3.1 billion |
Slight decline, market competition intensifies |
| 2025 |
$2.9 billion |
Cost pressures, market share shifts |
| 2026 |
$2.7 billion |
Approaching patent expiry |
| 2027 |
$2.5 billion |
Potential generic entry begins |
| 2028 |
$1.8 billion |
Post-generic price erosion |
| 2029 |
$1.5 billion |
Market stabilizes post-generic |
| 2030 |
$1.3 billion |
Market normalization |
Implications:
The imminent patent expiry will cause significant price decreases but may also expand accessible patient populations due to lower costs.
Key Takeaways:
- Gilenya remains a key player in MS treatment with steady sales.
- Patent expiration in 2027 is the primary catalyst for substantial price reductions.
- The competitive landscape and regulatory environment will influence long-term pricing.
- Market share is likely to shift toward generics from 2027 onward.
- Continued innovation and new formulations could alter pricing and market dynamics.
FAQs:
1. What is the current market price of Gilenya?
List prices are approximately $7,000 per month in the U.S., with net prices around $4,500-$5,000 after rebates.
2. When does Gilenya's patent expire?
Patent protections are expected to end around 2027-2028, subject to legal extensions.
3. How will generic entry affect the market?
Generics are projected to cause a 50-70% price decline within five years of launch.
4. What are Gilenya's main competitors?
Oral DMTs: Aubagio, Tecfidera, Mavenclad. Injectables like Tysabri also compete, with market share variations based on efficacy and safety profiles.
5. How is global demand expected to change?
MS prevalence is rising globally, which will support sustained demand, though pricing pressures and competition may limit revenue growth.
Sources:
- IQVIA. 2022 Global MS Market Report.
- Multiple Sclerosis International Federation. "Atlas of MS," 2022.
- U.S. Patent and Trademark Office. Patent expiration dates for Gilenya.
[1]: IQVIA. 2022.
[2]: MS International Federation. 2022.
[3]: USPTO patent database.
